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ABSTRACT
Molecular profiling and functional assessment of signalling pathways of advanced 
solid tumours are becoming increasingly available. However, their clinical utility in 
guiding patients’ treatment remains unknown. Here, we assessed whether molecular 
profiling helps physicians in therapeutic decision making by analysing the molecular 
profiles of 1057 advanced cancer patient samples after failing at least one standard 
of care treatment using a combination of next-generation sequencing (NGS), 
immunohistochemistry (IHC) and other specific tests. The resulting information was 
interpreted and personalized treatments for each patient were suggested. Our data 
showed that NGS alone provided the oncologist with useful information in 10–50% of 
cases (depending on cancer type), whereas the addition of IHC/other tests increased 
extensively the usefulness of the information provided. Using internet surveys, we 
investigated how therapy recommendations influenced treatment choice of the 
oncologist. For patients who were still alive after the provision of the molecular 
information (76.8%), 60.4% of their oncologists followed report recommendations. 
Most treatment decisions (93.4%) were made based on the combination of NGS and 
IHC/other tests, and an approved drug- rather than clinical trial enrolment- was the 
main treatment choice. Most common reasons given by physicians to explain the 
non-adherence to recommendations were drug availability and cost, which remain 
barriers to personalised precision medicine. Finally, we observed that 27% of patients 
treated with the suggested therapies had an overall survival > 12 months. Our study 
demonstrates that the combination of NGS and IHC/other tests provides the most 
useful information in aiding treatment decisions by oncologists in routine clinical 
practice. 
INTRODUCTION
Integration of genomic, transcriptomic and protein 
analyses is changing the diagnostic landscape of oncology 
[1–4]. A better choice for chemotherapies, targeted 
therapies and immunotherapies based on either specific 
genetic alterations, unusual protein expression or other 
biomarkers can be more effective and less toxic and 
costly [5]. This has been successfully demonstrated for 
a number of therapeutics targeting the protein products 
of specific genes that are altered in human solid cancers, 
such as Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2 or 
HER-2/neu) for trastuzumab, B-Raf Proto-Oncogene, 
Serine/Threonine Kinase (BRAF) for vemurafenib and 
dabrafenib, epidermal growth factor receptor (EGFR) for 
EGFR tyrosine kinase inhibitors or anti-EGFR antibodies, 
O-6-Methylguanine-DNA Methyltransferase (MGMT) 
promoter methylation status for temozolomide and, more 
recently, the expression of programmed death (PD) ligand 
1 (PD-L1) for anti-PD1 or anti-PD-L1 therapies in some 
solid tumours.
In addition to approved therapies, off-label 
indications and drugs being investigated in clinical 
trials can be used for treatment if there is knowledge of 
alterations in genes and protein expression that would 
drive the development and survival of the tumour [6]. 
Because the nature and functional effect of mutations 
and unusual protein expressions are unique to the cancer 
type and specific to its tumour microenvironment [7], it 
is critical to provide the most comprehensive overview of 
all this information in each patient’s cancer. Only then, 
a personalised treatment plan can be developed, which 
takes advantage of the clinical evidence regarding all 
the actionable alterations identified and how tumours 
harbouring them respond to the growing number of 
targeted/immune therapies alone or in combination with 
traditional chemotherapies.
The final goal of providing individualised 
information is to help oncologists choose the best 
treatment based on the most relevant information while 
minimising the amount of irrelevant information they are 
exposed to. To fulfil this aim, there are several challenges 
that need to be overcome: (i) each tumour contains 
inherited (germline) and tumour-specific (somatic) 
variants. Typically, only a few of the alterations are 
drivers, and so it is crucial to remove those that are only 
polymorphisms (not contributing to tumour progression). 
To eliminate inherited polymorphisms, sequencing of 
germline DNA is a feasible approach, but only when the 
focus is on either hotspot mutations or a small panel of 
genes. However, it is rarely performed routinely for cost 
reasons. With the increased number of genes included in 
cancer screening, the identification of those polymorphism 
(passenger) variants is becoming a bigger challenge. An 
important point to highlight here is that the necessity of 
identifying these polymorphisms is not only to determine 
the real driver mutations, but also for the use of those 
passenger mutations as surrogates for tumour monitoring 
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through liquid biopsy [8]; (ii) many tests are exclusively 
focussed on sequencing but the expression of some 
proteins or the presence of some specific biomarkers could 
be valuable in defining which strategy to implement and 
in assisting oncologists in making treatment decisions; 
(iii) there is uncertainty surrounding whether the receipt 
of such a complex report influences the oncologist’s 
treatment decisions, and whether such testing ultimately 
helps patients.
To evaluate the clinical use of such a multi-
dimensional approach, we gathered molecular data of 1057 
advanced tumour samples from patients who have already 
failed at least one standard of care treatment. These 
samples were analysed by: (i) sequencing of a solid biopsy 
only, with either a hotspot panel or a comprehensive 
panel including more than 400 genes; (ii) studying 
the expression of cancer-related proteins or specific 
biomarkers, as determined by immunohistochemistry 
(IHC) and other biomolecular tests (defined as “Package 
Plus” and described in more detail in the Materials 
and Methods section); or (iii) the combination of both 
approaches. In order to determine the utility of tumour 
profiling in routine clinical practice, we also investigated 
the final decision made by the oncologists after receiving 
the report of the molecular characterization of the tumour.
RESULTS
Using the above approach, we analysed 1057 
patients from 30 different countries on four continents, 
from January 2015 to January 2016. A total of 16,394 
different variants were found and classified into the five 
categories defined in Table 1.
After the comparison with the normal diploid 
population (see Materials and Methods), the percentage 
of “unknown” variants was reduced by half, independently 
of the tumour type. Figure 1 shows the resulting 
different percentages observed for each variant category 
according to cancer type. Of note, the most mutated genes 
observed in our analysis were TP53, KRAS and PIK3CA 
(Supplementary Figure 1).
The therapeutic impact of the NGS and/or the 
“Package Plus” tests
We interpreted the data from the NGS and/or the 
“Package Plus” tests for each patient, and then, based 
on a review of the clinical information published in the 
literature, the existing cancer treatments at that period 
were split into different independent categories based 
on potential for clinical benefit and on approval status 
(Table 2). A variant was considered to be associated with 
a treatment (positively or negatively) if it was damaging 
and there was clinical evidence for an association 
reported in the literature. As an example, pembrolizumab 
was classified as “approved for cancer type” and with 
“potential clinical benefit” in NSCLC with positive PD-
L1 expression.
We observed an average of 7.78% of samples 
rejected because of not enough quantity or bad quality of 
the material received (Figure 2A). When the proportion 
of variants with an associated treatment was determined 
(Figure 2B), approximately 30% of the samples examined 
using NGS only were associated with a treatment, but this 
percentage increased when variants were investigated 
using the “Package Plus” (80%) and the “Package Plus” 
and NGS combined (92%). The percentage of useful 
variants based on NGS only was highly associated with the 
cancer type, and more specifically with the most common 
cancers such as breast, colorectal and lung cancers 
(Figure 2C). In contrast to the data obtained with 
exclusively NGS, which provided no information 
on useful treatments in 50% to 90% of the cases, the 
percentage of useful treatments based on “Package Plus” 
was greater across the different cancer types (Figure 2C).
When NGS and “Package Plus” were combined, 
only sarcoma, carcinoma of unknown primary site 
and prostate cancer had samples that were without 
any associated treatment (40.7%, 19% and 26.3%, 
respectively; Figure 2C). All other cancer types were 
associated with treatment options after combining 
NGS and “Package Plus” results. Of note, most of the 
recommended treatments from the combined analysis were 
targeted therapies (53.8%), followed by chemotherapies 
(41.4%) and immunotherapies (4.8%). Nivolumab 
and pembrolizumab were the most recommended 
immunotherapies; within the category of chemotherapy, 
the main recommended treatments were taxanes (26%), 
doxorubicin/epirubicin (23%) and platinum-based 
therapies (10%); while PIK3CA/mTOR inhibitors (30%), 
MEK pathway inhibitors (30%) and anti-androgen (3%) 
were the main suggested treatments in the group of 
targeted therapy.
Influence of the molecular profiling results on 
oncologist´s treatment choice
Survey forms were sent to oncologists 3 months 
after the molecular profiling results were available, of 
which 255 were completed, meaning that approximately 
25% of the physicians participated. The oncologists who 
did not complete the survey form cited either an ethical 
reason (i.e. in their countries, providing an external 
organisation with such information is not allowed) or a 
“time” reason (too busy to complete a survey). Answers 
were received from oncologists worldwide (> 10 countries 
in 4 continents).
As shown in Figure 3A, 23.2% of the patients 
passed away before receiving any new treatment. Of 
the 76.8% of patients who were alive at the time of the 
survey, 60.4% of their oncologists followed the report 
recommendations, 32.3% did not, 3.1% followed some 
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and went against others, and 4.2% decided to treat their 
patient against report recommendations (meaning that 
they treated their patient with a treatment considered in the 
analysis as having a lack of clinical benefit) (Figure 3B).
In order to understand the reason behind the choice 
of not following the report’s recommendations, the 
oncologists’ answers were considered in more detail. The 
three main reasons given were: (i) the treatments advised 
are not available in my country, (ii) the treatments advised 
are not affordable in my country or (iii) I already chose a 
treatment before receiving your report. In this last case, 
even if our report agreed with the oncologist’s choice, it 
did not influence their decision.
In those cases for which oncologists provided 
treatment against recommendations, the answers were as 
follows: (i) I have other evidence, (ii) I do not have any 
other choice of treatment available in my country. 
Among the cases for which oncologists followed 
the report recommendations, the vast majority of the 
decisions were based either on the “Package Plus” only or 
on the combination of NGS and “Package Plus” (93.4%) 
(Figure 3C). Only 6.6% of the decisions were based on 
Table 1: Definitions of the categories of the variants
Variant categorya Definition
Damaging A variant for which several published studies demonstrated a functional impact on 
the protein (activating or inhibiting) and where clinical information is also available 
confirming the impact
Potentially damaging A variant for which only one publication has shown a functional impact based on an in 
vitro model and for which no clinical information is available
Unknown A variant for which there are no publications associated with a functional impact and 
that is not known as a SNP in the NCBI dbSNP database
Polymorphism
Rare polymorphism
A variant identified in the NCBI dbSNP database as a polymorphic variant with a minor 
allele frequency of at least 1%
A rare polymorphism is a variant found at less than 1% in population but that has been 
described as benign by functional analysis
aNote that this categorization applies comparably to somatic and germline variants.
dbSNP, Single Nucleotide Polymorphism Database; NCBI, National Center for Biotechnology Information; SNP, single 
nucleotide polymorphism.
Figure 1: Variants identified by NGS. All the variants were stratified by potential functional impact and by cancer type.
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the NGS results exclusively. We also analysed which 
treatments were chosen by the oncologists according to 
approval status (Table 2). Figure 3D shows that all the 
treatments prescribed by the oncologists were either 
approved for the cancer type analysed or approved for 
another cancer type. No investigational drug was chosen, 
and no one got enrolled in a clinical trial.
The follow-up questionnaires were also used to 
monitor how the information in the report could have 
impacted overall survival. We observed that in the cases 
for which our recommendations were followed, at least 
50% of the patients had an OS of > 6 months, and 27% of 
patients had a minimum OS of > 12 months (Figure 4). A 
lack of treatment response appeared to be mostly due to 
patients being considered for palliative treatment, where 
patients at this stage have an average OS of ~3–6 months 
[9, 10]; However, this result needs to be confirmed with 
larger follow-up data and other clinical efficacy endpoints. 
DISCUSSION
Overall, these data provide a comprehensive analysis 
of a potential precision medicine strategy, and information 
on its utility compared with objective decisions made in 
routine clinical practice by the treating oncologists. The 
results obtained show that the use of matched tumour and 
normal DNA for genomic analyses is a direct approach 
to potentially filter out non-pathogenic mutations and 
hence reduce the amount of irrelevant aberrations 
provided to physicians by at least 50%. This facilitates the 
Table 2: Definitions of the treatment categories
Category Definition
According to approval status
Approved for cancer type analysed Treatment approved by the FDA for the tumour type being analysed
Approved for other cancer type Treatment approved by the FDA for other tumour but not for cancer type 
being analysed
Under development Treatments in development, tested in phase II, II and IV clinical trials 
recruiting patients during 2016. These clinical trials (specifying altered 
genes or pathways within the inclusion criteria) were identified using 
ClinicalTrials.gov (https://clinicaltrials.gov/). 
According to clinical benefit
Potential clinical benefit (PCB) Treatments with evidence for a potential clinical benefit (either 
associated with a FDA recognized biomarker, present in guidelines 
or associated with strong clinical evidence). e.g. erlotinib for EGFR-
activating mutations in NSCLC, Larotrectinib for NTRK1-fusion solid 
tumours
Lack of potential clinical benefit (lack of PCB) Treatments associated with a resistance (e.g. Erlotinib in EGFR T790M 
mutant NSCLC) or standard of care treatments with no evidence for a 
potential clinical benefit due to absence of an alteration in the patient 
(e.g. Pembrolizumab in MSS CRC or in PD-L1 negative NSCLC)
Unknown clinical benefit (unknown PCB) Treatments with no strong evidence of efficacy (i.e. based only on 
preclinical data) or with contradictory evidence either found in the 
literature or based on patient pathway analysis (i.e. contradictory 
clinical benefit information found for the treatment after comparing the 
therapeutic impact of alterations detected by next-generation sequencing 
to those detected in “Package Plus” (IHC) in a sample)
Without treatment No alternative treatment can be recommended (i.e. no molecular 
alteration that could predict response or resistance to treatment was 
detected in the sample)
Categorization according to approval status takes into consideration if the treatment has been FDA approved and in which 
indications, or if it is still in clinical trial investigation.
Categorization according to clinical benefit evaluates the strength of evidence and the type of response to a treatment based 
on the presence of a specific molecular alteration.
Note that these 2 categories are independent. A treatment being classified according to the approval status does not 
automatically qualify it to any of the categories in clinical benefit. Indeed, a FDA approved drug can be classified as 
“unknown” clinical benefit if there is no strong evidence of clinical benefit to the aberration detected in the sample, or if there 
is contradictory evidence based on patient pathway analysis.
MSS: microsatellite stable.
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identification of clinically actionable somatic alterations in 
cancer specimens. However, in daily clinical practice and 
for cost reasons, only DNA from the tumour is sequenced. 
Moreover, these data highlight the added value of 
using a combination of molecular tests, with the integration 
of NGS and IHC/other specific tests data providing the 
most useful information regarding potential treatment 
options compared with any of those methods alone. The 
more information derived from the tests performed, the 
more useful the results can be; for example, in the current 
study the proportion of variants in prostate cancer for which 
there was no associated treatment was significantly reduced 
by the recent addition of the ARV7 test and the sequencing 
of BRCA1&2 into the “Package Plus” analysis (data 
not shown). On the other hand, the continued existence 
of variants with no treatment options in sarcoma and 
Figure 2: Categorisation of samples analysed. (A) Number of samples rejected and processed; (B) Patients with treatment options 
(approved for the cancer type analysed, approved for other cancer types or under development) and without, according to test; (C) The 
potential or lack of potential or the unknown potential clinical benefit of samples, according to test and cancer type. PCB, potential clinical 
benefit.
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carcinoma of unknown primary in the present study can be 
explained by the fact that there is no treatment available. 
However, further larger studies with more detailed survival/
treatment response metrics are needed to unravel whether 
it is the NGS data, “Package Plus” data or the integration 
of both that could better predict clinical benefit and more 
effectively impact clinical response.
The results of this work are in accordance with 
other studies that have also used molecular screening 
to identify potential personalised treatment options for 
patients with different advanced solid tumours [11–13]. 
While there is evidence that the use of precision medicine 
can improve treatment outcomes [9, 14, 15], barriers to 
its full implementation in routine clinical practice remain. 
These include the complexity of the molecular information 
generated by these tests, uncertainty surrounding the 
clinical utility of the information, lack of knowledge 
about precision medicine in general among healthcare 
professionals, and economic considerations such as cost 
and reimbursement structures affecting access to these 
tools [16–20], although the cost of DNA sequencing is 
decreasing. Moreover, the number of genes that can be 
sequenced is very large, and not all of these genes will 
have a practical application; as shown in the current study, 
the number of variants identified in the tumour samples as 
potentially useful was reduced by half when the tumour 
variants were compared with the ones found in a normal 
population. In the case of precision medicine, more 
information is not necessarily better, and techniques to 
reduce the information noise generated by these methods 
are paramount for increasing the usefulness of molecular 
information for physicians.
Figure 3: Results of oncologist survey. (A) Survival status of patients 3 months after provision of molecular results; (B) Treatment 
choices according and against recommendations; (C) Treatment modification stratified based on the test type; (D) Treatment choices 
according to treatment approval status.
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When investigating in this study the usefulness 
of the information provided to oncologists on their 
clinical decision-making process, it was observed 
that approximately two-thirds of treating oncologists 
followed the recommendations provided in the report. 
A minority of oncologists surveyed (4.4%) went against 
the recommendations. In 99% of the cases where our 
recommendations were not followed (excluding the cases 
where the oncologists went against them), the reason given 
was not related to scientific or clinical considerations, but 
rather to the barriers of drug availability and cost (the 
treatments are not available in my country; patients cannot 
afford the treatments because they are not reimbursed 
in my country) or for practical reasons, such as a lack 
of clinical trials for the recommended treatment being 
investigated in the oncologist’s country. The results 
obtained from the survey regarding treatment options 
chosen also reflected what is known about drug-related 
barriers to precision medicine, since in all the cases, the 
treatment given was either approved for the cancer type 
analysed or approved for another cancer type (mainly 
chemotherapies and few targeted or immunotherapies), 
and unfortunately, despite recommendations, no patient 
was assigned to clinical trials. 
This brings up an important point: many challenges 
of precision medicine in oncology, i.e. how to choose and 
deliver the right treatment(s) to the right person at the right 
time, can be best addressed through well-designed clinical 
trials. Genomic-based clinical trials (such as umbrella, 
basket, and adaptive trial design) can maximize the 
opportunity to allocate patients to the best treatment option 
based on the molecular profile and to study deeply clinical 
validity and utility of these allocations [21, 22]. That’s 
why it was disappointing to find in our study that none of 
the patients was enrolled in a trial. Besides lack of relevant 
clinical trials in the patient’s country, other barriers to 
enrolment that could have driven this decision were: 
preference of the oncologist to prescribe an approved 
drug over clinical trial (many of oncologists ordering our 
tests are from community hospitals and centers, and so this 
tendency is in accordance with published data [20, 23]); 
preference to enroll patients only in phase 3 studies (which 
were not available for all patients); and the very advanced 
stage of most patients (who had poor ECOG performance 
after failing multiple treatments) which would disqualify 
them from most trials. 
Interestingly, very few oncologists indicated that 
they made treatment decisions based on NGS alone, 
since NGS does not provide a lot of information on 
chemotherapies, which are the most readily available and 
cost-effective options available in most countries; this 
result reinforces the need for a multi-faceted approach 
towards precision medicine in routine clinical practice. 
Limitations of this analysis include its retrospective 
design and the lack of information regarding what would 
have been the treatment’s choice of the oncologists 
based only on their own knowledge and in the absence 
of the information provided. Another limitation is the 
low response rate for the follow-up surveys, that has also 
restricted the collection of important endpoints such as 
progression-free survival and time on therapy- important 
metrics to reinforce the value of the molecular tests on 
clinical utility. On the other hand, strengths include 
the number of samples analysed and the links made 
between the information provided and its influence on 
treatment choice. Further research is required, including 
the screening of more cancer types and prospective 
studies into the use and the clinical utility of this type 
Figure 4: Overall survival of patients. For the cases where our recommendations were followed (n = 114), the overall survival was 
analysed.
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of information to inform subsequent treatment; the 
questions of how to best treat patients with currently 
available treatments, how to encourage clinical trial 
participation, and how to address the issue of drug cost 
and reimbursement are yet unanswered.
In conclusion, this study suggests that a combination 
of tests analysing DNA, RNA and protein changes in 
tumours could represent the best approach for obtaining 
molecular information that would be useful to oncologists 
in routine clinical practice for guiding them towards 
alternative treatments. Despite the provision of this 
information to oncologists, barriers to full implementation 
of this approach remain, and include drug availability and 
cost, and low participation in clinical trials.
MATERIALS AND METHODS
Patient population
This work is a retrospective study evaluating 1057 
patients from 30 different countries on four continents 
with an advanced solid cancer who (1) had failed at least 
one line of therapy for their advanced disease before 
undergoing molecular profiling; and (2) had their tissue 
sample tested using OncoDEEP™ (80.43%) or OncoDEEP 
Clinical™ (19.57%) (OncoDNA, Gosselies, Belgium) 
profiling solutions from January 2015 to January 2016. All 
patients were suggested these solutions by their medical 
oncologists and were consented before the tissue was sent 
for molecular testing. These patients could have stage III 
or IV disease, and samples sent for molecular profiling 
were biopsies taken after progression on therapy and 
could be the primary (23.1%) or the metastatic (75.3%) 
tissue (in 1.6% of cases, the origin of the tissue was not 
specified). For objectivity, all samples were included in 
our analysis without a prior selection on age, cancer type, 
prior treatment, profiling results or follow-up data.
Samples
Tissue samples from different tumour types, as 
well as blood samples from 200 healthy individuals, 
were included in the analysis. A large range of cancer 
types were studied, including breast (18.8%), colorectal 
(15.1%), lung (12.6%), gynaecological (10.5%), sarcomas 
(6.5%), pancreatic (5.3%), renal (3.3%), gastric (3.3%), 
cholangiocarcinoma (3.2%), cancer of unknown primary 
(3%), brain (3%), prostate (2.6%), head and neck (2.5%), 
liver cancer (2.3%), melanoma (1.8%) and other rare 
cancers (6.1%) (Supplementary Table 1). The tumour 
biopsy sample was formalin-fixed paraffin-embedded 
(FFPE) tissues that was no older than 6 months. FFPE 
tissues underwent pathological review to determine if 
criteria were met: tumour tissue must be > 10% of the 
whole sample, the size of the tumour must be > 5 mm2, 
and the lymphocytes invasion must be < 20% in the 
region where the tumour cells are located. Tumours were 
macrodissected to remove any contaminating normal 
tissue.
Sample preparation and next-generation 
sequencing
DNA was extracted from FFPE tissue or blood using 
the Qiagen DNA FFPE Tissue Kit or Qiagen DNA Blood 
Mini Kit (Qiagen, Valencia, CA, USA), respectively. DNA 
quantity was measured using the Qubit 2.0 Fluorometer 
(Thermo Fisher Scientific, Waltham, USA).
To identify somatic alterations in tumour samples, 
we designed two Ampliseq custom panels (OncoDNA, 
Gosselies, Belgium) to amplify by NGS, either 207 
amplicons covering hotspot mutations of 65 genes 
(OncoDEEP™: updated version of the Ion Ampliseq 
Cancer Hotspot Panel v2) or > 16,452 amplicons covering 
whole exons of 409 genes (OncoDEEP Clinical™: Ion 
Ampliseq Comprehensive Cancer Panel) (Supplementary 
Table 2). Briefly, the targeted sequencing libraries 
were generated using the Ion AmpliSeq Library kit 2.0 
according to the manufacturer’s instructions (Thermo 
Fisher Scientific, Waltham, USA). The starting material 
consisted of either 10 ng (OncoDEEP™) or 50 ng 
(OncoDEEP Clinical™) from FFPE samples depending 
on the panel chosen, while normal DNA extracted from 
blood was always analysed with OncoDEEP Clinical™. 
The primers used for amplification were partially digested 
by the Pfu enzyme. The product of digestion was then 
ligated with corresponding barcoded adapters and 
purified using Ampure Beads (Agilent Genomics Inc). 
The product of purification was amplified for 5 more 
cycles and subsequently purified using Ampure Beads. 
The quality of the libraries was assessed using the Qubit 
dsDNA HS Assay kit (Thermo Fisher Scientific, Waltham, 
USA). 10 pM of each library was loaded into the IonChef 
system (Thermo Fisher Scientific, Waltham, USA) for 
the emulsion polymerase chain reaction (PCR) and then 
loaded in the chip. An average coverage of 1000x was 
targeted to be able to detect variants down to 5% for the 
FFPE and blood samples. We used either the Personal 
Genome Machine (PGM), the Proton or the 5XL devices 
(Thermo Fisher Scientific, Waltham, USA) to sequence 
depending on the required throughput.
Primary processing of next-generation 
sequencing data and identification of putative 
somatic mutations
The data generated from the FFPE and normal 
DNA samples were first aligned to the human reference 
sequence and annotated using the Consensus Coding DNA 
Sequences (CCDS), RefSeq, and Ensembl databases. 
NGS data were then analysed by using the Torrent Suite 
Software (Thermo Fisher Scientific, Waltham, USA). 
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Next, somatic mutations were identified with the Variant 
Caller 4.0 software using the somatic high stringency 
parameters (Thermo Fisher Scientific, Waltham, USA) to 
ensure sufficient coverage of the analysed bases and to 
exclude mapping and sequencing errors (Supplementary 
Table 3). Mutation analysis was focussed on single-base 
substitutions as well as small insertions and deletions. 
Candidate somatic mutations were further filtered based 
on: coverage of > 100; a forward-reverse ratio of 10%, 
90%; gene annotation to identify those occurring in 
protein-coding regions; the exclusion of intronic and 
silent changes; and the retention of mutations resulting 
in missense mutations, nonsense mutations, frame shifts, 
or splice site alterations. A manual visual inspection step 
was used to further remove artefactual changes. Mutations 
were separated into those associated with a described 
biological impact on the function of the proteins and those 
common germline mutations found in the NCBI dbSNP 
human variation sets in VCF (variant call format) version 
138 (https://www.ncbi.nlm.nih.gov/variation/docs/human_
variation_vcf/) labelled as “common” with a germline 
minor allele frequency of ≥ 0.01 and annotated as having 
“no known medical impact.” The remaining mutations 
(with no described biological impact and not present 
in NCBI dbSNP database) were compared to the set of 
variants identified in the normal diploid population (blood 
samples) and labelled as “polymorphism” if found in it.
Analysis of immunohistochemistry results and 
other biomolecular tests
For 80% of the patients, an additional bundle of IHC 
(Supplementary Table 4) and other molecular tests were 
performed (called “Package Plus”). All the alterations 
tested in this package are directly related to patient´s 
response towards different kinds of treatment. Moreover, 
this tests’ combination is personalized to the patient since 
it takes into account the tumour type, the biomarkers 
already tested and the previous treatment[s] given. Each 
IHC was analysed by microscopy in a double-blind 
fashion. A score was calculated based on a predefined 
ISO-accredited scoring method (which is IHC dependent) 
and the consensus of both analyses was used to define 
the level of expression or activation of the proteins. The 
other biomolecular tests considered were methylation of 
the MGMT promoter, the expression of either EGFRVIII, 
MET Proto-Oncogene, Receptor Tyrosine Kinase (MET)-
exon 14 deletion or androgen-receptor splice variant 7 
messenger RNA (ARV7) as determined by quantitative 
PCR, and microsatellite instability testing by Genescan® 
analysis (Thermo Fisher Scientific, Waltham, USA).
Clinical relevance of the analyses
A literature search was performed to identify FDA 
(Food and Drug Administration) labels, official guidelines 
(National Comprehensive Cancer Network), and 
retrospective and prospective clinical studies (published 
in PubMed or as conference abstracts), pertaining to 
genomic alterations of each gene and their association 
with outcomes in cancer patients, and to remove variants 
not known to be damaging or potentially damaging 
(Table 1). To keep our internal variant database updated 
with the newest published data on these mutations, an 
automatic search was done daily, and then its results were 
curated by scientific experts. Variants were sorted into four 
categories according to their impact on the functionality 
of the corresponding protein (Table 1). This functional 
impact classification of the mutations and their clinical 
actionability was then compared to that of OncoKB [24]. 
OncoKB is an openly accessible, expert-guided precision 
oncology knowledge database that assigns each variant to 
1 of 5 levels of evidence corresponding to its actionability. 
For this analysis, variants were considered actionable and 
associated with clinical benefit if they ranked as levels 1–3 
(i.e. associated with a standard therapy or investigational 
therapy) or level R1 (i.e. associated with resistance to a 
standard therapy) in OncoKB.
Moreover, all tests included in the “Package Plus” 
investigate alterations that rank as levels 1–3 or R1. The 
treatments recommended for each patient according to 
the molecular profile fell into three different categories: 
“Approved for cancer type analysed”, “Approved for other 
cancer type” and “Under development” (Table 2). 
Of note, once the patient’s sample passed the quality 
control (explained above), it takes a maximum of seven 
working days for the report (that includes treatment/
clinical trial suggestions) to be ready. The physician can 
access the report via a proprietary online interface, and 
download it as a PDF document.
Oncologist survey
To determine whether the provision of the 
tumour genetic profiling, immunohistochemistry and 
other biomolecular test results influenced oncologist´s 
treatment decisions, an automatic system (web-based) was 
developed to ask the following questions:
1. Did the patient pass away before the application 
of the treatment?
2. Have you changed the treatment decision on the 
basis of the results generated by OncoDEEP™/OncoDEEP 
Clinical™?
3. Have you prescribed one or several drugs 
suggested in our report (either approved or tested in 
clinical trial)? If yes, which one(s)? If not, why?
These questions were sent to the oncologists via 
email 3 months after the biomolecular results were 
available. Participation in the survey was voluntary and 
uncompensated.
New surveys were automatically sent after the initial 
one every 3–4 months to follow-up on how the patient was 
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responding to treatment. There were 114 cases where the 
oncologist who followed our therapy recommendations 
provided us with the follow-up information, either until 
cut-off of the analysis (January 2016) or until patient 
deceased. For these 114 cases, overall survival (OS) was 
analysed. OS was defined as the time from initial testing 
(study enrolment) to January 2016 or to death due to any 
cause.
Abbreviations
NGS, next-generation sequencing; IHC, 
immunohistochemistry; FFPE, formalin-fixed paraffin-
embedded; FDA, Food and Drug Administration; OS, 
overall survival; PCR, polymerase chain reaction; dbSNP, 
Single Nucleotide Polymorphism Database; SNP, single 
nucleotide polymorphism; PCB, potential clinical benefit.
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